We are live on
!
Find out more
EIM
Essex Investment Management Portfolio holdings
AUM
$632M
1-Year Est. Return
95.36%
This Fund
S&P 500
This Quarter
Est. Return
+31.23%
1 Year Est. Return
+95.36%
3 Year Est. Return
+271.62%
5 Year Est. Return
+354.98%
10 Year Est. Return
+3,586.14%
AUM
$550M
AUM Growth
+$70.6M
(+15%)
Cap. Flow
-$37M
Cap. Flow
% of AUM
-6.73%
Top 10 Holdings %
Top 10 Hldgs %
19.32%
Holding
327
New
24
Increased
23
Reduced
152
Closed
29
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Mirum Pharmaceuticals
MIRM
|
+$5.02M |
| 2 |
GE Vernova
GEV
|
+$2.92M |
| 3 |
Cohu
COHU
|
+$2.47M |
| 4 |
Mama's Creations
MAMA
|
+$2.39M |
| 5 |
Orion Group Holdings
ORN
|
+$2.25M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
NUTX
Nutex Health
NUTX
|
+$7.08M |
| 2 |
ITCI
Intra-Cellular Therapies Inc.
ITCI
|
+$6.56M |
| 3 |
Travere Therapeutics
TVTX
|
+$4.56M |
| 4 |
Generac Holdings
GNRC
|
+$3.88M |
| 5 |
Guidewire Software
GWRE
|
+$3.34M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Industrials | 30.33% |
| 2 | Technology | 26.01% |
| 3 | Healthcare | 18.4% |
| 4 | Financials | 6.04% |
| 5 | Consumer Staples | 4.36% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
301
Evolus
EOLS
$536M
| – | – |
-181,134
| Closed | -$2.18M |
|
302
Frontdoor
FTDR
$5.89B
| – | – |
-58,703
| Closed | -$2.26M |
|
303
Forward Air
FWRD
$658M
| – | – |
-76,596
| Closed | -$1.54M |
|
304
Grid Dynamics Holdings
GDYN
$632M
| – | – |
-138,742
| Closed | -$2.17M |
|
|
305
Generac Holdings
GNRC
$13.1B
| – | – |
-30,615
| Closed | -$3.88M |
|
|
GTLS
306
DELISTED
Chart Industries
GTLS
| – | – |
-8,578
| Closed | -$1.24M |
|
307
Hannon Armstrong Sustainable Infrastructure Capital
HASI
$5.37B
| – | – |
-49,063
| Closed | -$1.43M |
|
308
Hubbell
HUBB
$27.1B
| – | – |
-3,785
| Closed | -$1.25M |
|
|
IAS
309
DELISTED
Integral Ad Science
IAS
| – | – |
-128,408
| Closed | -$1.03M |
|
310
inTEST
INTT
$179M
| – | – |
-22,774
| Closed | -$159K |
|
311
Pulmonx
LUNG
$98.4M
| – | – |
-303,246
| Closed | -$2.04M |
|
|
NINE
312
DELISTED
Nine Energy Service
NINE
| – | – |
-126,360
| Closed | -$143K |
|
313
InspireMD
NSPR
$40.3M
| – | – |
-72,565
| Closed | -$195K |
|
314
NovoCure
NVCR
$2.05B
| – | – |
-121,040
| Closed | -$2.16M |
|
315
Pfizer
PFE
$150B
| – | – |
-114,116
| Closed | -$2.89M |
|
316
Pixelworks
PXLW
$42.3M
| – | – |
-5,039
| Closed | -$37.9K |
|
317
QuidelOrtho
QDEL
$1.02B
| – | – |
-63,315
| Closed | -$2.21M |
|
318
Revolve Group
RVLV
$1.69B
| – | – |
-110,322
| Closed | -$2.37M |
|
319
Sidus Space
SIDU
$253M
| – | – |
-30,112
| Closed | -$44.6K |
|
320
Tarsus Pharmaceuticals
TARS
$3.07B
| – | – |
-54,447
| Closed | -$2.8M |
|
321
Interface
TILE
$2.23B
| – | – |
-142,578
| Closed | -$2.83M |
|
|
322
Travere Therapeutics
TVTX
$5.86B
| – | – |
-254,666
| Closed | -$4.56M |
|
|
AIOT
323
PowerFleet Inc
AIOT
$421M
| – | – |
-356,972
| Closed | -$1.96M |
|
|
ITCI
324
DELISTED
Intra-Cellular Therapies Inc.
ITCI
| – | – |
-49,717
| Closed | -$6.56M |
|
Similar funds
BI
KCMH
SFM
VIM
AP
TTSTC
WCM
FTC
Essex Investment Management's Q2 2025 Portfolio in Review
As of Q2 2025, Essex Investment Management held 327 positions worth $550M, up 15% from $479M the previous quarter. Its ten largest holdings account for 19% of the portfolio.
Essex Investment Management withdrew a net $37M in Q2 2025, closing 29 positions and reducing 152 holdings. Its most notable exit was Intra-Cellular Therapies Inc., an estimated $6.56M position sold in full.
By sector, the portfolio is most concentrated in Industrials at 30% of assets, up from 25% a quarter earlier, followed by Technology and Healthcare.
Against the trend, Essex Investment Management opened a new position in Mirum Pharmaceuticals worth $5.74M.
- Essex Investment Management's largest Q2 2025 buy was Mirum Pharmaceuticals: 112,731 shares worth $5.74M.
- Essex Investment Management added most to GE Vernova in Q2 2025, an estimated $2.92M increase.
- Essex Investment Management's biggest Q2 2025 reduction was Nutex Health, cutting an estimated $7.08M.
- Essex Investment Management fully exited Intra-Cellular Therapies Inc. in Q2 2025, selling an estimated $6.56M.
- Essex Investment Management's ten largest holdings make up 19% of its $550M portfolio in Q2 2025.
- Essex Investment Management opened 24 new positions and closed 29 in Q2 2025.
- Essex Investment Management's portfolio value rose 15% quarter-over-quarter to $550M.
Based on Essex Investment Management's 13F filing for Q2 2025, filed 12 Aug 2025.